July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Change of baseline visual acuity in eyes with age-related macular degeneration from 2006-2015
Author Affiliations & Notes
  • Tomoko Sawada
    Ophthalmology, Shiga University of Medical Science, Otsu, Shiga, Japan
  • Tsutomu Yasukawa
    Ophthalmology, Nagoya City University, Japan
  • Hiroko Imaizumi
    Ophthalmology, Sapporo City General Hospital, Japan
  • Hisashi Mastubara
    Ophthalmology, Mie University, Japan
  • Kazuhiro Kimura
    Ophthalmology, Yamaguchi University, Japan
  • Hiroto Terasaki
    Ophthalmology, Kagoshima University, Japan
  • Hiroto Ishikawa
    Ophthalmology, Hyogo College of Medicine, Japan
  • Tomoya Murakami
    Ophthalmology, University of Tsukuba, Japan
  • Masaru Takeuchi
    Ophthalmology, National Defense Medical College, Japan
  • Yoshinori Mitamura
    Ophthalmology, Tokushima University, Tokushima, Japan
  • Mariko Yamashita
    Nara Medical University, Japan
  • Yoshihiro Takamura
    Ophthalmology, University of Fukui, Japan
  • Toshinori Murata
    Ophthalmology, Shinshu University, Japan
  • Jiro Kogo
    Ophthalmology, St. Marianna University School of Medicine, Japan
  • Taiji Sakamoto
    Ophthalmology, Kagoshima University, Japan
  • Masahito Ohji
    Ophthalmology, Shiga University of Medical Science, Otsu, Shiga, Japan
  • Footnotes
    Commercial Relationships   Tomoko Sawada, Allergan (R), Bayer (R), Novartis Pharma (R), Santen (R); Tsutomu Yasukawa, Alcon Japan (R), Alcon Pharma (F), Alcon Pharma (R), AMO Japan (R), Baseconnect Inc. (R), Bausch & Lomb Japan (R), Bayer (R), CRESCO (R), HOYA (F), HOYA (R), NIDEK (F), NIKKEN SOHONSHA (R), Nitten (R), Novartis Pharma (R), ONO PHARMACEUTICAL (R), Pfizer (R), Santen (R), SANWA KAGAKU KENKYUSHO (R), Senju (R); Hiroko Imaizumi, None; Hisashi Mastubara, Bayer (R), Novartis Pharma (F), Novartis Pharma (R), Santen (R), Senju (R); Kazuhiro Kimura, Bayer (R), Novartis Pharma (R), Pfizer (R), Santen (R); Hiroto Terasaki, Alcon Pharma (F), Alcon Pharma (R), Bayer (R), JFC Sales Plan (R), Santen (R); Hiroto Ishikawa, Alcon (F), AMO (R), Santen (R); Tomoya Murakami, None; Masaru Takeuchi, None; Yoshinori Mitamura, Alcon Japan (F), AMO Japan (F), Pfizer (F), Santen (F); Mariko Yamashita, None; Yoshihiro Takamura, None; Toshinori Murata, Alcon Pharma (F), Bayer (F); Jiro Kogo, None; Taiji Sakamoto, Alcon Japan (R), Alcon Japan (F), Bayer (R), Bayer (F), Bayer (C), Graybug (R), Novartis (C), Novartis Pharma (R), Novartis Pharma (F), Santen (R), Santen (F), Santen (C), Senju (R), Senju (F), Senju (C), TOPCON (P); Masahito Ohji, Alcon Japan (F), Alcon Japan (R), Allergan (C), Baseconnect Inc. (R), Bayer (R), Bayer (C), HOYA (F), HOYA (C), Kowa (R), Novartis (F), Novartis (R), Novartis (C), Otsuka (F), Otsuka (R), Pfizer (F), Pfizer (R), Rise Evolution (R), Santen (F), Santen (R), Santen (C), Senju (F), Senju (R), TOPCON (R), Zeiss (R)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 1160. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Tomoko Sawada, Tsutomu Yasukawa, Hiroko Imaizumi, Hisashi Mastubara, Kazuhiro Kimura, Hiroto Terasaki, Hiroto Ishikawa, Tomoya Murakami, Masaru Takeuchi, Yoshinori Mitamura, Mariko Yamashita, Yoshihiro Takamura, Toshinori Murata, Jiro Kogo, Taiji Sakamoto, Masahito Ohji; Change of baseline visual acuity in eyes with age-related macular degeneration from 2006-2015. Invest. Ophthalmol. Vis. Sci. 2019;60(9):1160. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To investigate 10-year change of baseline visual acuity in eyes with treatment-naïve neovascular age-related macular degeneration (AMD).

Methods : Retrospective and multicenter review of patients with treatment-naïve neovascular AMD who initiated treatment with either photodynamic therapy (PDT), anti-vascular endothelial growth factor (VEGF) (pagaptanib, ranibizumab or aflibercept) or PDT with anti-VEGF from 2006 to 2015. The best-corrected visual acuity (BCVA) at baseline was converted to the logarithm of the minimum angle of resolution (logMAR) visual acuity. Baseline visual acuity was evaluated over time using one way ANOVA, Kruskal-Wallis test and Dunn's multiple comparisons test.

Results : 3,294 eyes of 3,101 patients were included. Mean age was 73.9 ± 8.8 years. Mean BCVA in logMAR at baseline was 0.78 ± 0.45 (n=153) in 2006, 0.75 ± 0.46 (n=169) in 2007, 0.63 ± 0.38 (n=123) in 2008, 0.60 ± 0.43 (n=255) in 2009, 0.55 ± 0.44 (n=388) in 2010, 0.49 ± 0.42 (n=402) in 2011, 0.52 ± 0.43 (n=434) in 2012, 0.47 ± 0.41 (n=462) in 2013, 0.46 ± 0.40 (n=426) in 2014, and 0.44 ± 0.42 (n=482) in 2015. The BCVA at baseline in 2006 was significantly worse than any other BCVA from 2009 to 2015 (p <0.0001). The BCVA at baseline in 2007 was significantly worse than any other BCVA from 2009 to 2015 (p <0.0001).

Conclusions : The BCVA with AMD before initial treatment tended to become better over the years.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×